On February 12, 2020 Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, reported that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 9th Annual SVB Leerink Global Healthcare Conference in New York City on Wednesday, February 26, 2020, at 1:00 p.m. Eastern time (Press release, Castle Biosciences, FEB 12, 2020, View Source [SID1234554227]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the company’s presentation will be available by visiting Castle Biosciences’ website at View Source A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.

On February 12, 2020 BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, reported the dates for several key events (Press release, BioLife Solutions, FEB 12, 2020, View Source [SID1234554244]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Q4 & FY2019 Earnings Conference Call

The Company’s fourth quarter and full year 2019 financial results will be released after market close on Wednesday, March 11, 2020 and the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company’s financial results and a general business update.

To access the webcast, log on to the Investor Relations page of the BioLife Solutions website at www.biolifesolutions.com/earnings. Alternatively, you may access the live conference call by dialing (844) 825-0512 (U.S. & Canada) or (315) 625-6880 (International) with the following Conference ID: 9098230. A webcast replay will be available approximately two hours after the call and will be archived on www.biolifesolutions.com for 90 days.

Investor Conferences

Cowen 40th Annual Healthcare Conference; March 2-4, 2020: Boston Marriott Copley Place
2020 Stephens West Coast 1×1 Conference; March 12, 2020: The Palace Hotel, San Francisco
Oppenheimer 30th Annual Healthcare Conference; March 17-18, 2020: InterContinental New York Barclay
B. Riley FBR’s 21st Annual Institutional Investor Conference; May 20-21, 2020: Beverly Hilton
Scientific Conferences

CAR TCR Summit Europe; February 24-27, 2020: Hotel Novotel London West
Innate Killer Summit 2020 | Hanson Wade; March 24-26, 2020: Westin San Diego
Advanced Therapies Congress & Expo; March 30 – April 1, 2020: Business Design Centre, London
Massachusetts Association of Blood Banks (MABB); April 7-8, 2020: Mansfield, MA
American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting; April 24-29, 2020: San Diego Convention Center
American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting; May 12-15, 2020; Hynes Convention Center, Boston
Allogeneic Cell Therapies Summit 2020 | Hanson Wade; May 19-21, 2020; Sheraton Boston Hotel
ISCT Annual Meeting; May 27-30, 2020: Palais des congres de Paris, France

On February 12, 2020 Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, reported that the company will participate in the upcoming SVB Leerink 9th Annual Global Healthcare Conference (Press release, Ascendis Pharma, FEB 12, 2020, View Source [SID1234554211]). Company executives will provide a business overview and update on the company’s pipeline programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details

Event SVB Leerink 9th Annual Global Healthcare Conference
Location New York
Date Tuesday, February 25, 2020
Time 11:30 a.m. Eastern Time
A live webcast of the presentation will be available in the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.

On February 12, 2020 X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, reported that the United States Patent and Trademark Office (USPTO) has issued United States Patent No. 10,548,889, which is expected to provide exclusivity of X4’s lead therapeutic candidate, mavorixafor (X4P-001), through 2038 (Press release, X4 Pharmaceuticals, FEB 12, 2020, View Source [SID1234554228]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This new patent which covers critical compositions of matter enhances our already robust patent portfolio, further strengthening and extending the potential commercial horizon for mavorixafor," said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. "We expect that this long patent runway will assist us in maximizing the full therapeutic potential of mavorixafor, which we are currently investigating across a number of rare disease indications."

About Mavorixafor

X4 Pharmaceuticals’ lead product candidate, mavorixafor (X4P-001), is a potential first-in-class, once-daily, oral inhibitor of CXCR4, currently in a Phase 3 clinical trial for the treatment of WHIM syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. Mavorixafor has demonstrated proof-of-concept in WHIM syndrome in a Phase 2 clinical trial, including clinically meaningful increases in neutrophil and lymphocyte biomarker counts, as well as a trend of reduction in infection rates and wart burden, and a favorable safety profile. Mavorixafor was recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with WHIM syndrome, and was granted orphan drug status by the FDA in 2018 and by the European Commission in 2019 for the treatment of WHIM syndrome. Mavorixafor is also being developed by X4 to treat Severe Congenital Neutropenia (SCN), Waldenström’s macroglobulinemia (WM), and clear cell renal cell carcinoma (ccRCC).

On February 12, 2020 Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading company in leveraging computational biology to design novel products for life-science-based industries including: human health, agriculture and industrial applications, reported that it will release its financial results for the fourth quarter and full year of 2019 on Wednesday, March 4, 2020 (Press release, Evogene, FEB 12, 2020, View Source [SID1234554245]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On the day of the announcement, the Company’s management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-668-9141 toll free from the United States, or +972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company’s website at www.evogene.com.

A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-326-9310 toll free from the United States, or +972-3-925-5904 internationally. The replay will be accessible through March 4, 2019, and an archive of the webcast will be available on the Company’s website.